Proto-Oncogene Proteins c-cbl
"Proto-Oncogene Proteins c-cbl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proto-oncogene proteins that negatively regulate RECEPTOR PROTEIN-TYROSINE KINASE signaling. It is a UBIQUITIN-PROTEIN LIGASE and the cellular homologue of ONCOGENE PROTEIN V-CBL.
| Descriptor ID |
D050721
|
| MeSH Number(s) |
D08.811.464.938.750.374 D12.776.624.664.700.172
|
| Concept/Terms |
Proto-Oncogene Proteins c-cbl- Proto-Oncogene Proteins c-cbl
- Proto Oncogene Proteins c cbl
- c-cbl, Proto-Oncogene Proteins
- RING Finger Protein 55
- c-cbl Protein
- cbl Proto-Oncogene Protein
- Proto-Oncogene Protein, cbl
- cbl Proto Oncogene Protein
- CBL E3 Ubiquitin Protein Ligase
- c-cbl Proto-Oncogene Protein
- Proto-Oncogene Protein, c-cbl
- c cbl Proto Oncogene Protein
- RNF55 Protein
- Proto-Oncogene Protein c-cbl
- Proto Oncogene Protein c cbl
- c-cbl, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-cbl".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-cbl".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-cbl" by people in this website by year, and whether "Proto-Oncogene Proteins c-cbl" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 6 | 6 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-cbl" by people in Profiles.
-
Cbl-b deficiency prevents functional but not phenotypic T cell anergy. J Exp Med. 2021 07 05; 218(7).
-
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
-
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
-
Recruitment of Cbl-b to B cell antigen receptor couples antigen recognition to Toll-like receptor 9 activation in late endosomes. PLoS One. 2014; 9(3):e89792.
-
E3 ubiquitin ligase Cbl-b suppresses proallergic T cell development and allergic airway inflammation. Cell Rep. 2014 Feb 27; 6(4):709-23.
-
Cbl-b mediates TGFß sensitivity by downregulating inhibitory SMAD7 in primary T cells. J Mol Cell Biol. 2013 Dec; 5(6):358-68.
-
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer. 2011 Dec 01; 117(23):5344-50.
-
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
-
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972.
-
T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol. 2008 Apr; 28(7):2470-80.